Yong‐Mi Kim

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Sajid Khan, Xuan Zhang, Dongwen Lv et al. · Nature Medicine · 2019 · 608 citations · Full text

Oncology, Medicine, Potent Antitumor Activity +7

IT Outsourcing Strategies: Universalistic, Contingency, and Configurational Explanations of Success

Jae-Nam Lee, Shaila M. Miranda, Yong‐Mi Kim · Information Systems Research · 2004 · 427 citations

Individual Outsourcing Decisions, Residual Rights Theory, Ict Governance +19

Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen–presenting cells

Markus Y. Mapara, Yong‐Mi Kim, Shengping Wang et al. · Blood · 2002 · 237 citations · Full text

Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells

M.-s. Jung, Jin Kyung Rho, Yong‐Mi Kim et al. · Oncogene · 2012 · 201 citations

Tumor Biology, Medicine, Stem Cell Mobilization +9

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition

Cihangir Duy, Christian Hurtz, Seyedmehdi Shojaee et al. · Nature · 2011 · 200 citations · Full text

Hematological Malignancy, Cancer Research, Mixed-phenotype Acute Leukemia +7